Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
about
Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulationsStructural and kinetic analysis of drug resistant mutants of HIV-1 proteaseCrystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistanceLack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseViability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapyDesign, Synthesis, Protein−Ligand X-ray Structure, and Biological Evaluation of a Series of Novel Macrocyclic Human Immunodeficiency Virus-1 Protease Inhibitors to Combat Drug ResistanceStructure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugsDicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.Prediction of mutational tolerance in HIV-1 protease and reverse transcriptase using flexible backbone protein designStatistical potentials for fold assessment.Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.Design and synthesis of potent macrocyclic HIV-1 protease inhibitors involving P1-P2 ligands.Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.21st century natural product research and drug development and traditional medicinesRole of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivityEmergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detectionCatalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.Structure of equine infectious anemia virus proteinase complexed with an inhibitor.Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization.Anti-human immunodeficiency virus drug combination strategies.Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.Effectiveness of commercial inhibitors against subtype F HIV-1 protease.Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.Incorporating target heterogeneity in drug designResistance proof, folding-inhibitor drugs
P2860
Q24794072-3B09E3F9-C432-4F87-BD71-D4ABC93DD499Q27619254-27B75A66-CF72-44CE-9944-6A27C7271113Q27628785-03AE075A-7A12-4A13-8D63-9F9BE9C59034Q27637329-885379D0-24A7-4613-9ED7-94BE024653C4Q27640250-2DCA5927-9F68-4832-953E-D9D786CDC875Q27657395-D040B06C-B55A-475D-97E6-27E9CF4E0AD7Q27748828-9E66AAFF-F138-43A3-A566-40CD303DB42AQ28379316-D3B9EF48-BA85-4941-8214-1229DE46692BQ28914732-62BA850F-27D2-41F0-9E0E-0614F1EEA070Q30329417-538A9A57-9BAC-406E-88B0-5518FA32C5F8Q33814096-E8D29493-AC3A-49BC-B309-0A6D568BBD46Q34046931-1CA8A6C2-D84A-4953-BF58-C1DD66C47E98Q34334101-FE75FBFA-10C5-474B-A628-7811FC893A7EQ34602021-59762A85-BE28-435F-9282-D21D55AF2BF5Q34717635-72FC229F-BFA3-4FD1-B8C4-6A68F592186EQ35129066-4092A1A8-26F9-48D8-ADB8-CA0577CBDA50Q35927934-8599A840-FEAE-4B24-B339-7D50B57547F1Q36280005-E71EA5EE-0804-4042-B54F-EEB97F8B05E0Q36315090-C5E33C3D-57CF-46DC-9A4C-A81CE811182EQ37018369-CC850E9E-7DBF-400A-88E8-B07A535E2A12Q37247555-DF133BBF-34CF-4061-BD39-9CE93D875F23Q37583444-5019C6F4-B45A-471E-ABD5-6C84F5A3887EQ37980084-0783571A-9ADF-4CFE-BB52-78FCFF2E45BDQ41815076-13DDB378-486F-4EF4-A039-945D3AABA848Q41993329-973AB14A-0E26-4591-9929-0FEFCEC0E2E3Q42552199-21F946CD-33E6-4F05-8789-D428C8725443Q43686780-4DA52473-7B7A-414A-A787-F45A407ED335Q45752028-0D1051E9-10B8-4B4F-A24F-31088B1809BFQ45765743-3ED6AADC-4617-4DC5-A96B-E9738548015CQ46339842-744664F6-9E83-464A-BCED-160262414A5AQ54162409-1659FD0A-26BB-445C-843A-E652569C914BQ58023123-E2F9BE49-96D3-4CE8-8A9F-86758D9B19E5Q58882333-FF6B5BFF-F2FC-4024-A5DE-ACAF24DD81F0
P2860
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
description
1995 nî lūn-bûn
@nan
1995 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մարտին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@ast
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@en
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@nl
type
label
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@ast
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@en
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@nl
prefLabel
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@ast
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@en
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@nl
P2093
P2860
P356
P1476
Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
@en
P2093
E T Baldwin
J W Erickson
N Pattabiraman
P2860
P356
10.1038/NSB0395-244
P577
1995-03-01T00:00:00Z